Publicaciones (21) Publicaciones en las que ha participado algún/a investigador/a

2017

  1. A Prospective Observational Study for Assessment and Outcome Association of Circulating Endothelial Cells in Clear Cell Renal Cell Carcinoma Patients Who Show Initial Benefit from First-line Treatment. The CIRCLES (CIRCuLating Endothelial cellS) Study (SOGUG-CEC-2011-01)

    European Urology Focus, Vol. 3, Núm. 4-5, pp. 430-436

  2. A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)

    Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624

  3. A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study

    Oncotarget, Vol. 8, Núm. 42, pp. 73144-73153

  4. Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC

    Journal of the National Cancer Institute, Vol. 109, Núm. 9

  5. Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain

    Clinical and Translational Oncology, Vol. 19, Núm. 6, pp. 667-681

  6. Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain

    Clinical and Translational Oncology, Vol. 19, Núm. 12, pp. 1454-1461

  7. DNMT1 is predictive of survival and associated with Ki-67 expression in R-CHOP-treated diffuse large B-cell lymphomas

    Pathology, Vol. 49, Núm. 7, pp. 731-739

  8. Effectiveness and safety of Eribulin in metastatic breast cancer

    European Journal of Clinical Pharmacy, Vol. 19, Núm. 1, pp. 55-59

  9. Epithelial ovarian cancer and primary peritoneal carcinomatosis in the elderly: What is our clinical practice?

    European Journal of Gynaecological Oncology, Vol. 38, Núm. 5, pp. 695-699

  10. Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM “El Álamo III” retrospective study

    PLoS ONE, Vol. 12, Núm. 10

  11. Functional proteomics outlines the complexity of breast cancer molecular subtypes

    Scientific Reports, Vol. 7, Núm. 1

  12. Gemcitabine–erlotinib versus gemcitabine–erlotinib–capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group

    European Journal of Cancer, Vol. 75, pp. 73-82

  13. Hereditary pancreatic cancer: Related syndromes and clinical perspective

    Hereditary Cancer in Clinical Practice, Vol. 15, Núm. 1

  14. Long-term follow-up of The Intergroup Exemestane Study

    Journal of Clinical Oncology, Vol. 35, Núm. 22, pp. 2507-2514

  15. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    The Lancet Oncology, Vol. 18, Núm. 12, pp. 1688-1700

  16. Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma

    Oncotarget, Vol. 8, Núm. 18, pp. 30410-30421

  17. Oncogenic activity of SOX1 in glioblastoma

    Scientific Reports, Vol. 7

  18. Predictive and prognostic brain metastases assessment in luminal breast cancer patients: FN14 and GRP94 from diagnosis to prophylaxis

    Frontiers in Oncology, Vol. 7, Núm. DEC

  19. Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population

    Stem Cell Reports, Vol. 8, Núm. 5, pp. 1392-1407

  20. Review of pharmacogenetics studies of L-asparaginase hypersensitivity in acute lymphoblastic leukemia points to variants in the GRIA1 gene

    Drug Metabolism and Personalized Therapy, Vol. 32, Núm. 1, pp. 1-9